Bismuth Subsalicylate vs Durvalumab

## Bismuth Subsalicylate vs Durvalumab: Overview

This comparison examines the pharmacological differences between **Bismuth Subsalicylate** and **Durvalumab**.

## Mechanism of Action

**Durvalumab**: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.

## Pharmacokinetics

**Half-life**: Bismuth Subsalicylate — N/A; Durvalumab — 17 days.

## Chemical Properties

**Type**: Bismuth Subsalicylate — Small molecule; Durvalumab — Antibody.